Travere Therapeutics heads into its May 7 earnings with a striking divergence: short sellers have been exiting while analysts race to raise targets, leaving the stock 47% higher than a month ago with defensive options hedging as the only note of caution.
The short side tells a story of retreat. Short interest has fallen nearly 6% over the past week and more than 4% over the past month, now running at 14.2% of the free float — still a meaningful level, but directionally easing. Borrow availability remains wide and inexpensive, with cost to borrow at just 0.55%. That low cost, combined with falling short positions, points to a market where bears are reducing exposure rather than pressing their bets. The borrow pool is far from stressed.
Options traders are less relaxed. The put/call ratio has climbed to 1.14, about 1.5 standard deviations above its 20-day average of 0.91 — the clearest sign of defensive positioning in months. That shift tracks the stock's 47% one-month rally to $44.91; investors who rode the move higher are hedging against a pullback. The PCR remains well below its 52-week peak of 1.53, so the hedging is elevated but not extreme.
The analyst community has moved decisively in one direction. Across April, Guggenheim twice raised its target — most recently to $56 — while Citigroup lifted its target to $53 and Canaccord moved to $56. The consensus mean target sits at $50, implying modest upside from current levels after the recent run, though the Street's direction of travel has been uniformly higher. JP Morgan is the outlier, trimming its target to $41 in late March while holding an Overweight rating. Bulls are focused on Filspari's commercial trajectory in rare kidney disease and the company's strong cash position. Bears point to commercialization risk, potential patient access constraints in active Nephrotic Syndrome, and the possibility of needing to return to capital markets.
The insider picture adds a layer of complexity. The CEO sold roughly $2.6 million of stock on April 15, joined by the Chief Legal Officer and CFO. Net insider activity over the past 90 days reflects cumulative selling of approximately $11.5 million in value — a pattern consistent with executives monetising gains after a sharp price advance rather than signalling fundamental concern, though the cluster of C-suite sales on the same day is worth noting.
The May 7 print is therefore less a test of whether Filspari's approval narrative holds, and more a question of whether early commercial data justifies a stock that has nearly doubled from its recent lows.
See the live data behind this article on ORTEX.
Open TVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
